MedPal AI Enhances Health OS with eMARx Acquisition, Paving Way for Nationwide UK Care Home Deployment

eMARx: The Digital Medication Backbone in UK Care Homes

eMARx serves as the digital system of record for medication administration across UK care homes. Its software platform schedules, barcode-verifies, records, and audits every administered dose in real time, replacing traditional paper medication charts and significantly reducing medication errors at the point of care. Operating bedside dose by dose, eMARx provides immediate visibility into medication administration throughout care home environments. This digital innovation addresses longstanding challenges in medication management that previously relied on manual charting systems.

The timing of this acquisition is strategic, considering the extensive medication use in UK care homes. Approximately 331,000 residents aged 65 and over receive NHS prescriptions monthly, with an average of 6.8 medicines per resident and over 20% prescribed ten or more medications. NHS England estimates around 250,000 emergency hospital admissions annually from care home residents, with 35-40% deemed avoidable, often linked to over-medication and medication errors. By digitizing and integrating the medication pathway—from prescription through robotic dispensing to barcode-verified bedside administration—MedPal's leadership believes this acquisition effectively tackles medication errors and missed doses while enhancing oversight for clinicians and families.

MedPal's Unified Health OS and Market Differentiation

MedPal's strategy focuses on creating a single AI-native health operating system that connects every stage of a patient’s medication journey. Before acquiring eMARx, MedPal operated NHS Distance Selling Pharmacy hubs at Sarus Court, Runcorn (a 23,000 sq ft robotic dispensing center) and Swaffham, alongside a B2B care home pharmacy supply business anchored by Care UK, New Health (a GLP-1 weight management clinic), and Juno, an AI health companion built on Anthropic’s Claude. With eMARx integrated, MedPal now offers care homes a seamless service where medicines are prescribed, robotically dispensed at Sarus Court, delivered to the home, and administered with a live digital record, complemented by Juno’s AI-driven alerts, reordering, and family communication.

The company asserts no other UK provider offers such a comprehensive integrated service. Typically, eMARx is a standalone cost for care homes; however, by embedding it within its Health OS, MedPal plans to offer eMARx at discounted or zero cost if care homes exclusively use MedPal’s pharmacy services. This approach is expected to boost pharmacy revenues, accelerate care home customer acquisition, and improve retention. Jason Drummond, MedPal’s Founder and CEO, stated, "This is the deal that completes our Health OS," emphasizing the ability to deliver "one integrated service that gets the right medicine to the right resident at the right time, every time, with families able to trust that their loved ones are safe."

Financial Strength and Recurring Revenue Model of eMARx

Prior to acquisition, eMARx demonstrated profitability and a robust recurring revenue model. For the year ended 31 March 2026, eMARx posted unaudited revenue of a3739,231, a 19% increase year-on-year and nearly triple its revenue from three years earlier. Profit after tax was a3106,273, with net assets of a3283,834 as of 31 March 2026. The gross margin of approximately 82% highlights a highly profitable business with strong operating leverage.

Most revenue derives from recurring monthly software subscriptions, providing MedPal with predictable income streams beyond its traditional pharmacy dispensing and supply services. This acquisition adds a software-as-a-service revenue component that is less dependent on transaction volumes. The six eMARx employees joining MedPal bring vital expertise in care home software operations and client relations.

Scalability of Sarus Court and Expanding Market Potential Across 16,500 UK Care Homes

Sarus Court’s robotic dispensing hub, equipped with BD Rowa technology operating at 99.9% reliability, was designed for high-volume automated dispensing and currently has significant spare capacity. This infrastructure enables MedPal to scale well beyond its existing Care UK partnership. eMARx provides a software-driven entry point into thousands of additional care homes, creating a synergistic growth cycle where each new eMARx client is a prospective pharmacy supply customer and vice versa.

The UK care home sector includes about 16,500 homes with approximately 530,000 beds and nearly half a million residents. An independent valuation estimates this market at a327 billion for 2025/26, with demand expected to increase substantially over the next decade. Medicines are central to care home operations and NHS expenditure, with NHS England spending a321.6 billion on medicines in 2024/25, including a310.3 billion prescribed in primary care. This large, growing market represents a significant opportunity for MedPal’s integrated solution across many care homes currently outside eMARx’s footprint.

Established Customer Base and Market Penetration of eMARx

eMARx brings an established customer base spanning national care groups such as Care UK, pharmacy groups, and numerous independent care homes. This existing footprint offers MedPal an immediate installed base and a proven product, mitigating execution risks associated with broader market rollout beyond the Care UK relationship. Founded in 2020 and registered in England and Wales (company number 12540468), eMARx has been refined over six years in the competitive care home software market.

John Richardson, eMARx’s founder, remarked, "eMARx has been my passion since the day we wrote the first line of code, and as I approach retirement my priority was to find the right custodian for the platform, our customers and the team that built it. In MedPal we have found exactly that." All seven eMARx shareholders, including five operational team members, will be locked-in MedPal shareholders for 12 months, aligning incentives with the Group’s expansion plans.

Transaction Details and Share Issuance

MedPal acquired all issued shares of Solid State Technologies Ltd for approximately a3380,000 in initial consideration, comprising a3133,066 in cash and a3247,000 via issuance of 7,272,834 new ordinary shares ("Consideration Shares"). A customary completion accounts adjustment of about a394,000 is expected, to be settled roughly 35% in cash (a332,900) and 65% in additional shares (a361,100), raising total consideration to approximately a3474,000. Total share issuance may increase if the adjustment is fully settled in shares.

The Consideration Shares were priced at 3.4 pence each, matching MedPal’s closing mid-market price on 17 July 2026. All shares are subject to a 12-month lock-up and orderly market arrangements, preventing free sale during this period. Admission to trading on AIM for the 7,272,834 shares is expected on or around 23 July 2026. Post-admission, MedPal’s enlarged issued share capital will total 777,113,860 ordinary shares, serving as the basis for shareholder interest notifications under FCA rules.

Strategic Fit and Management Integration

The deal reflects strong strategic alignment between MedPal and eMARx’s management. All seven eMARx shareholders, including five operational team members, agree to a 12-month lock-up, ensuring continuity and commitment to integration and national rollout. John Richardson’s endorsement signals confidence in MedPal as the platform’s steward.

By incorporating six eMARx employees, MedPal strengthens its expertise in electronic medication administration systems, care home client relations, and software support. This management continuity reduces execution risk for expanding eMARx’s reach and integrating it with MedPal’s dispensing infrastructure and Juno AI companion. Details on broader management integration remain undisclosed.

NHS Spending and Avoidable Hospital Admissions Context

The announcement highlights NHS spending and health outcomes underpinning the acquisition rationale. NHS England spent a321.6 billion on medicines in 2024/25, with a310.3 billion prescribed in primary care. Approximately 331,000 care home residents aged 65+ receive NHS prescriptions monthly, averaging 6.8 medicines each, with over 20% prescribed ten or more medications.

NHS England estimates care home residents account for roughly 250,000 emergency hospital admissions annually, 35-40% of which are avoidable, driven partly by over-medication and errors. MedPal’s integrated Health OS aims to reduce medication errors, prevent missed doses, and enhance oversight, aligning with NHS priorities to lower avoidable admissions and improve medicines management in social care. This approach potentially reduces NHS costs and improves resident outcomes.

Regulatory and Market Considerations

The announcement does not specify any required regulatory approvals from the Care Quality Commission or other health regulators for the acquisition or integration. Admission of Consideration Shares to AIM is expected around 23 July 2026, indicating no prolonged regulatory or shareholder approval delays. No information was provided on outstanding conditions precedent or transaction completion status.

Competitive responses and market condition impacts on rollout were not disclosed. Immediate share price effects remain unclear. Forward-looking statements include risks such as economic conditions, staffing competition, regulatory processes, technical challenges, legislation changes, and execution uncertainties. Scaling eMARx across the care home market and integrating it with pharmacy services present significant execution risks for investors.